Date: 2016-09-15
Type of information: Licensing agreement
Compound: combination of cytokines for use in the expansion, selection and enrichment of TIL (tumor infiltrating lymphocyte) products
Company: Lion Biotechnologies (USA - CA) PolyBioCept (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: cell therapyy/immunotherapy product
Disease: glioblastoma, pancreatic cancer
Details: * On September 15, 2016, Lion Biotechnologies announced that it has entered into an exclusive license agreement with PolyBioCept AB, a corporation organized under the laws of Sweden, and a related clinical trials agreement to sponsor two clinical studies in glioblastoma and pancreatic cancer at the Karolinska University Hospital in Sweden. Under the terms of the license agreement, Lion gained exclusive worldwide rights to two international patent applications related to a specific combination of cytokines for use in the expansion, selection and enrichment of TIL products for the treatment of multiple cancer indications. Lion also has co-exclusive worldwide rights (with PolyBioCept) to make genetically engineered TIL using the cytokine cocktail for use in multiple cancer indications. Under the terms of the clinical trials agreement, Lion will fund two clinical studies in glioblastoma and pancreatic cancer to be conducted at the Karolinska University Hospital in which TIL is manufactured using the licensed combination of cytokines.
Financial terms: Lion will pay PolyBioCept $2.5 million in upfront payments under the exclusive license. Lion will also make additional payments (in cash and in shares of Lion's common stock) upon achievement of certain clinical, regulatory and sales milestones. The clinical trials agreement calls for a total of $1.7 million to be paid to the Karolinska University Hospital and PolyBioCept to conduct the clinical trials in glioblastoma and pancreatic cancer.
Latest news:
